多索茶碱与噻托溴铵粉联合治疗慢阻肺对肺功能的影响研究

Effect of Doxofylline Combined with Tiotropium Bromide Powder on Pulmonary Function in Patients with COPD

目的探讨并分析慢阻肺治疗中采用多索茶碱与噻托溴铵粉联合治疗方案的临床疗效及对患者肺功能的影响。方法选取河南省商丘市第一人民医院收治的120例慢阻肺患者展开研究,所有患者均为2020年9月至2022年8月期间接收的,随机将其分为两组,即对照组(多索茶碱治疗)和实验组(多索茶碱与噻托溴铵粉联合治疗),每组60例,比较两组患者的治疗结局。结果治疗后,实验组的肺功能明显优于对照组(P<0.05);实验组的炎症因子指标水平明显低于对照组(P<0.05);实验组的不良反应发生率为5.00%,显著低于对照组的26.66%(P<0.05);实验组的治疗总有效率为95.00%,明显比对照组的78.33%更高(P<0.05);实验组生活质量各维度的评分均高于对照组(P<0.05)。结论在慢阻肺治疗中联合多索茶碱与噻托溴铵粉两种药物除了能够改善患者的肺功能之外,还能在一定程度上减轻患者的肺部炎症,提高患者的生活质量,从而可保障治疗工作的安全性和有效性。

Objective to explore and analyze the clinical efficacy of the combined treatment regimen of doxophylline and diltiazem ammonium bromide dust in the treatment of chronic obstructive pulmonary disease(COPD)and the effect on patients'lung function.Methods 120 patients with chronic obstructive pulmonary disease admitted to the First People's Hospital of Shangqiu City,Henan Province were selected for the study,all patients were received between September 2020 and August 2022,and were randomly divided into two groups,i.e.,the control group(doxophylline treatment)and the experimental group(doxophylline and tiotropium bromide powder combination treatment),with 60 cases in each group,to analyze and compare the treatment results of the patients in the two groups.Results After treatment,the lung function of the laboratory group was appreciably better than that of the control group(P<0.05);the level of inflammatory factor indexes in the laboratory group was obviously lower than that of the control group(P<0.05);the incidence rate of adverse reactions in the laboratory group was 5.00%,which was appreciably lower than that of the control government(P<0.05);and the overall effective rate of treatment in the laboratory group was 95.00%,which was obviously higher than that of the control group(P<0.05),which was 78.33%(P<0.05).higher(P<0.05);the scores of all dimensions of quality of life in the experimental group were higher than those in the control group(P<0.05).Conclusion In addition to improving the lung function of patients,the two drugs,doxophylline and diethylcarbinol,can also reduce lung inflammation to a certain extent and improve the quality of life of patients in the treatment of chronic obstructive pulmonary disease(COPD),which can guarantee the safety and effectiveness of the treatment work.